How I treat cancer-associated venous thromboembolism

Slides:

Advertisements

Similar presentations

Farmaci usati prima dellintervento Basi farmacologiche del loro uso La prevenzione del tromboembolismo.

Advertisements

Evidence-Based Management of Anticoagulant Therapy

Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.

CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.

LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.

Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.

Study Guide Guide for Patients Undergoing Anticoagulant Therapy.

Venous Thromboembolism

DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?

Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.

Warfarin Efficacy in Cancer Patients on Long-term Anticoagulation Neha Doshi, PharmD Candidate LeAnn B. Norris, PharmD, BCPS P. Brandon Bookstaver, PharmD,

Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.

Thalidomide-based Regimens: Rates of VTE* in Newly Diagnosed MM Treatment No Prophylaxis Any Prophylaxis ASA Warfarin mg/d Prophylactic LMWH Therapeutic.

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

Prevention of Venous Thromboembolism in Orthopedic Surgery Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy.

Outpatient DVT assessment & treatment Daniel Gilada.

How I treat recurrent deep-vein thrombosis by Paul A. Kyrle Blood Volume 127(6): February 11, 2016 ©2016 by American Society of Hematology.

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

Venous thrombosis , why should I care ?

Assessment of the Effect of Target Specific Oral Anticoagulants for Treatment of Venous Thromboembolism in Oncology Patients Good morning. My name is.

Evidence-Based Management of Anticoagulant Therapy

Clinical Professor in Palliative Medicine

The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,

Volume 130, Issue 6, Pages (December 2006)

Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved.

Ortho Warfarin Dosing Protocol

Prevention of Venous Thromboembolism in Orthopedic Surgery Patients

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use by Ida Martinelli, Anthonie W. A. Lensing, Saskia.

Thrombosis, Cancer, and NOACs

Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

How I treat elderly patients with myeloma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

A Case Challenge: Anticoagulant Choices for Acute PE

New Oral Anticoagulants and VTE Management

Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis Paloma López-Beret, MD, Antonio Orgaz, MD,

VTE Treatment Conventional Approach

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer

Don't look now! Risk stratify first

Succinct Review of the New VTE Prevention and Management Guidelines

Extraordinary Cases of VTE Prevention in Patients With Cancer

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F

A Systematic Review of Pulmonary Embolism in Patients With Lung Cancer

Cancer-Associated Thrombosis

by Alex C. Spyropoulos, and James D. Douketis

Venous Thromboembolism (VTE)

A meta-analysis of anticoagulation for calf deep venous thrombosis

Periprocedural Management of Patients on Anticoagulation

Direct Oral Anticoagulants vs Low-Molecular–Weight Heparin for Thromboprophylaxis in Nonoperative Pelvic Fractures Mohammad Hamidi, MD, Muhammad Zeeshan,

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Disease Burden of VTE Phases of VTE Treatment.

Thrombophilia in pregnancy: Whom to screen, when to treat

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.

How I treat heparin-induced thrombocytopenia and thrombosis

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Potential protocol for the treatment of pulmonary embolism (PE), incorporating direct oral anticoagulants (OACs). Potential protocol for the treatment.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

by Lapo Alinari, and Kristie A. Blum

A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia by Leslie Skeith, Marc Carrier, Risto Kaaja,

Balancing bleeding in brain metastases

Presentation transcript:

How I treat cancer-associated venous thromboembolism by Noémie Kraaijpoel, and Marc Carrier Blood Volume 133(4):291-298 January 24, 2019 ©2019 by American Society of Hematology

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested treatment algorithm for catheter-related thrombosis in cancer patients. *In patients with isolated single subsegmental PE without concomitant DVT, consider withholding anticoagulant therapy in patients at high risk of bleeding. **Edoxaban is initiated after a LMWH lead-in of at least 5 days. §Assess drug-drug interactions and bleeding risk during follow-up and consider changing the anticoagulant treatment regimen accordingly. †The decision to continue anticoagulant treatment beyond 6 months should also balance the risk of recurrent VTE and bleeding complications in combination with patients’ preference, life expectancy, and treatment costs. ¥LMWH is currently the preferred treatment option. DOAC, direct oral anticoagulant; LMWH, low-molecular-weight heparin. Noémie Kraaijpoel, and Marc Carrier Blood 2019;133:291-298 ©2019 by American Society of Hematology